Article
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.
Signal transduction and targeted therapy - 2 Feb 2026
Zhang Fan, Zheng Zhendong, Zhang Hongmei, Yan Xiaolong, Liu Zhefeng, Yang Fan, Wen Juyi, Gan Xin, Wu Lin, Cang Shundong, Wang Hongmei, Zhao Jun, Peng Liang, Li Xiaosong, Fan Zaiwen, Shen Ge, Zhou Qiong, Zou Jinjing, Xu Yu, Zhang Lei, Zhao Mingfang, Cai Shangli, Hu Yi
Abstract excerpt
Inactivating vascular endothelial growth factor receptor (VEGFR) may improve the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). The ATTENTION study (phase II, open-label, randomized, multicenter trial (Registration number: ChiCTR2100047453), evaluated the efficacy and safety of aumolertinib plus apatinib vs. aumolertinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.